Panaeolus cyanescens

Psychedelics and Women’s Health

The bourgeoning interest surrounding the therapeutic use of psychedelic drugs to treat mental conditions is still a new field of exploration. It’s an ideal time for discussing the unique health and mental health needs of women and how psychedelics may be able to help. Sharp students of the finer points of psychedelic research may ask if the entourage effect is different in women than in men (and maybe pre- and postmenopausal, too). Keeping this focus will help prevent women from being neglected in psychedelic research.

Historically, the unique needs (and physiology) of women have been underrepresented, ignored, or purposely excluded from drug development and clinical trials.1,2 Also, few female scientists have been involved in drug research, including psychedelic research. Fortunately, it’s not too late to shift this paradigm as psychedelic research steams ahead.

Matthew Johnson, associate professor of psychiatry and behavioral sciences at Johns Hopkins says of his psychedelic research,3

We are seeing a demographic shift, particularly among women. We’ve had more females in our studies.

The Health Needs of Women

The mental health needs and everyday challenges of women are many, unique, and the statistics are somewhat frightening.

According to the American Psychiatric Association, every year, one in five women in the US has a mental health problem such as depression, post-traumatic stress disorder (PTSD), or an eating disorder.4 Depression is the most common mental health issue for women, and twice as many women experience depression in their lifetime than men. Also, women are twice as likely to experience anxiety and PTSD than men. Of people suffering from anorexia or bulimia, 85%-95% are women and women account for 65% of those with binge eating disorders.

The World Health Organization (WHO) says these statistics hold true for women worldwide.5Depression, anxiety, psychological stress, domestic and sexual violence, and escalating rates of substance abuse are affecting women more than men on a global basis. The WHO estimates that 80% of the 50 million people around the world affected by civil wars, violent conflicts, disasters, and displacement are women and children. At least one in five women worldwide will be the victim of rape or attempted rape in their lifetime, leading to a variety of mental conditions, including PTSD, depression, and anxiety.

And it’s not just women’s mental health. Women’s overall health also includes pregnancy, breastfeeding, menstruation, post-partum depression, perimenopause, menopause, and coping with miscarriage, stillbirth, and the death of a child, to name a few. This article is not suggesting that women should use psychedelics during pregnancy and breastfeeding, although women are curious and asking questions about it.6 The point is that ideally, it may be beneficial to treat the overall health needs of women as a separate entity in psychedelic research and give it equal (if not a higher) priority.

Magic Mushrooms and Women’s Health

A July 2019 article in Marie Claire called attention to the growing trend of women self-treating their mental health issues by microdosing psilocybin mushrooms (aka magic mushrooms or psychedelic mushrooms).7 They microdose to treat their PTSD, depression, anxiety, and ADHD (attention-deficit/hyperactivity disorder), among other conditions. The women say traditional pharmaceuticals did not work for them or made it feel like they were just walling off the issue, and still not feeling better. Microdosing magic mushrooms made the women feel they could face and deal with the issues that were causing their symptoms. The women weren’t cured, but as a microdosing photographer put it,

When I do have bad days, I’m able to separate myself from a feeling of worthlessness and stop telling myself the story that I shouldn’t try to connect, shouldn’t be curious, shouldn’t create. Microdosing helps me recognize that I’m still whole.

Another woman said,

I processed my emotions and let them go in a few hours.

Psilocybin, the most famous compound in magic mushrooms, is effective for relieving the symptoms of treatment-resistant depression (TRD) and is currently in phase 2 clinical trials.8 Of course, there are women participating in this study, and the data may show some differences in the results between men and women. However, research looking exclusively at women and magic mushrooms or pure psilocybin is lacking.

Cannabis and Women’s Health

A 2017 survey conducted by the Cannabis Consumers Coalition received 15% more women respondents than men. Also, the data showed that more women (53%) than men (42%) smoked pot, dramatically different results from surveys that usually find men dominating cannabis consumption. In spite of its popularity with women, a survey of 1,530 women found about 70% believe there is a stigma associated with cannabis consumption and about 66% hide the fact that they use it.9

The research and development of cannabis products has opened a whole new world for women searching for effective ways to improve their health and treat their health issues. According to a 2017 survey by BDS Analytics, the top reasons women give for cannabis self-care are menstruation, menopause, and enhancement of their sexual experience.10 Last year, Forbes reported on “How Self-Care and Women’s Health are Shaping the Cannabis Industry.” 11 Anna Duckworth, a co-founder of Miss Grass magazine, told Forbes,

The industry is starting to recognize that women consumers need high-quality products that seamlessly fit into their lives in a way that can replace a bad habit like drinking too much alcohol to unwind or taking a pill to go to sleep.

Currently, the literature does not indicate much research interest in the effectiveness of marijuana or the compounds in it for treating mental health or other conditions from a woman’s perspective. Cannabis has been shown to alleviate symptoms that overlap with the physical and emotional symptoms of premenstrual syndrome (PMS) and premenstrual dysmorphic disorder (PMDD), but studies evaluating the effects of cannabis or its components on PMS and PMDD specifically are lacking.12 There is one study in progress at Harvard University where researchers are evaluating the effects of broad-spectrum CBD (cannabidiol) on menstrual pain.13

MDMA and Women’s Health

MDMA (3,4-methylenedioxyemethamphetamine) presents an excellent example of why women should be considered separately in psychedelic research. The 2016 US Global Drug Survey found that female British clubbers were 2-3 times more likely to seek emergency treatment than men after using MDMA (ecstasy). There was also a 4-fold increase in the last three years in emergency room visits for women who had used MDMA.14 Researchers theorize that the cause may be related to women’s unique body chemistry. A 2001 study found the psychoactive effects of MDMA in women were more intense than those of men, possibly due to women being more susceptible to the serotonin-releasing effects of MDMA.15 The effects reported included perceptual changes, thought disturbances, and the fear of loss of body control. The dose of MDMA was positively correlated with the intensity of the effects. Women also had more adverse effects and outcomes from MDMA than men.

The Future of Psychedelics for Women

There is an unmet need for research to discover and understand the unique effects of psychedelic compounds in women and to create formulations with precise amounts of specific ingredients. The research going on now is groundbreaking and critical for the overall understanding of psychedelic therapy. But, consider these questions when it comes to women’s health and psychedelics. Are there are formulations with certain combinations of magic mushroom compounds that would be more effective for treating depression, anxiety, and PTSD in women (i.e., Is the entourage effect different in women than men)? Is microdosing different for women? How? Are specific set, settings, and music more effective for women undergoing psychedelic therapy?

The growing popularity of women self-treating with psychedelics and finding relief is a trend that should not be ignored. At the same time, the uniqueness of female physiology calls for specialized research to provide the best possible therapies.

Liberty Caps

5 Women in Psychedelics You Should Know About

Badass women making waves in the psychedelic movement, from research to drug policy reform

Michelle Janikian // Dec. 2, 2019

Women have always played an integral role in psychedelic healing and research, even if they haven’t always been highlighted as mavericks in the field. But as the “Psychedelic Renaissance” goes mainstream, it’s time to start recognizing groundbreaking women in psychedelic science and activism. The five women we’ve chosen to feature are all actively changing the landscape of psychedelics, from developing leading theories in how they work, to advocating for fair access for all. These women, among many other women and gender non-conforming folk, are shifting the way society and science view these substances and bringing forth a new generation of doctors, researchers, and policymakers, with psychedelics at the core.

Ann Shulgin

DoubleBlind: Ann Shulgin

Born in 1931, Ann Shulgin is often seen as a matriarch of the psychedelic movement. Before MDMA was classified as a Schedule I substance in 1985, and then 2C-B in 1995, Shulgin provided psychedelic-assisted therapy with these substances for many in the Bay Area using her expertise in Jungian psychology. She is the widow of the renowned chemist, Alexander “Sasha” Shulgin, who had a license from the DEA to essentially invent new psychedelic compounds and test them on himself, synthesizing over 230 new psychoactive compounds in the process, including 2C-B. Together, they co-wrote two classic psychedelic books,PIHKAL: A Chemical Love Story and TIHKAL: The Continuation, detailing those substances, including their own rating scale to judge the personal effects. Ann Shulgin is also the Founder of Transform Press, has contributed to many other books and publications on the subject, including Ecstasy: The Complete Guide andThe Secret Chief Revealed, and continues to write and speak on psychedelic issues.

Monnica Williams

DoubleBlind: Monnica Williams

Monnica Williams, Ph.D., is a clinical psychologist, researcher and professor who’s dedicated to expanding psychedelic-assisted therapy access to minorities and people of color (POC). She’s a trained MDMA-assisted therapist and has worked on Multidisciplinary Association for Psychedelic Studies (MAPS) PTSD trials, including the only site exclusively available to POC. As an expert in race-based trauma, Williams is working with MAPS on making MDMA-assisted therapy more inviting and inclusive to marginalized communities by training more therapists of color and tweaking certain aspects of the protocol, like the language and music used. Williams is also the Clinical Director of the Behavioral Wellness Clinic in Connecticut as well as the Associate Director of the Chacruna Institute for Psychedelic Plant Medicines, a publication and organization that bridges the divide between sacred entheogenic traditions and current psychedelic science. To bring light to racial disparities and cultural differences in treating anxiety disorders, Williams has authored over 100 peer-reviewed papers as well as articles and book chapters in her field.

How to Grow Mushrooms 101 – DoubleBlind Online Course

Learn how to grow mushrooms at-home through our online course complete with 7 video episodes, a mushroom legality guide, support from the DoubleBlind mycology experts, and more!

How To Grow Mushrooms Course Now On Sale! Let’s Grow.

Buy Now

Rosalind “Ros” Watts

DoubleBlind: Ros Watts

Rosalind Watts, Ph.D. is the clinical lead of groundbreaking trials on psilocybin for depression at Imperial College London. Through her experience guiding many psilocybin-assisted therapy sessions in her work at Imperial, she has written several key scientific papers on the subjective psilocybin experience and psychological mechanisms of post-trip changes. Themes she explores in her work, like psilocybin’s ability to connect people with themselves, others, and the world, and to help people move from “avoidance to acceptance” of difficult emotions, is shaping how the psychedelic and scientific communities explain how mushrooms work for relieving mental health conditions. Based on this work, Watts has recently developed the ACE Model (Accept, Connect, Embody) to provide psychedelic therapists with a framework on how to work with a depressed population.

Bia Labate

DoubleBlind: Bia Labate of Chacruna

Bia Labate, Ph.D., is an anthropologist from Brazil with a focus on psychoactive substances, drug policies, shamanism, and religion. She is involved in the psychedelic movement as the Executive Director of Chacruna, and organizes and speaks at many events in the community. Labate is also the Public Education and Culture Specialist at MAPS, adjunct professor at the California Institute of Integral Studies (CIIS), visiting professor at the University of Guadalajara, Mexico, and author of over 20 books and several peer-reviewed papers. She is a huge proponent of including more diverse voices in the psychedelic community, especially of queer, women/non-binary, Latinx, and indigenous folks in these important and societal-shifting conversations.

Natalie Ginsberg

DoubleBlind: Natalie Ginsberg of MAPS

Natalie Lyla Ginsberg, M.S.W., is the Director of Policy and Advocacy at MAPSwhere she lobbies in support of cannabis and psychedelic research and policy change. She is dedicated to building and organizing the psychedelic community as well as pushing these issues to the front of social change. Ginsberg originally got involved in advocacy work after her experience as a social worker in low-income neighborhoods in New York City where she became frustrated with systemic failures making it impossible for her clients to succeed. Before joining MAPS in 2014, she worked as a policy fellow with the Drug Policy Alliance and helped to bring medical cannabis to New York state in an attempt to end racist marijuana arrests. Now, in coordination with MAPS and Imperial College London, she is co-developing a psychedelic peace-building strategy between Israelis and Palestinians, inspired by the potential of these substances to heal systemic, intergenerational trauma and build community.

Michelle Janikian is a journalist focused on drug policy, trends and education. She’s the author of the upcoming book, “Your Psilocybin Mushroom Companion: An Informative, Easy-to-Use Guide to Understanding Magic Mushrooms”, writes a column for Playboy about psychedelics and cannabis and has also contributed to High Times, Herb, Rolling Stone and Teen Vogue.

Join Our Community

psilocybe Tempensis

Is microdosing mushrooms going mainstream?

Before the school run, or commuting to work, increasing numbers are taking tiny doses of psychedelic drugs in the UK. Why?

Headshot of lecturer Lindsay Jordan
Lindsay Jordan: ‘It was as if a whole new world opened up for me.’ Photograph: Richard Saker/The Guardian
Penis Envy Magic Mushroom

Psilocybin mushrooms “Magic Mushrooms”

This sheet talks about using psilocybin mushrooms (“Magic Mushrooms”) in a pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider.

What are Psilocybin mushrooms (“magic mushrooms”)?

The term magic mushrooms refer to mushrooms with hallucinogenic properties (causing changes in your reality) that are taken as an illegal drug. Psilocin and psilocybin are the hallucinogenic components found in certain types of mushrooms. Psilocybin mushrooms are sometimes called other names such as caps, shrooms, and buttons. Magic mushrooms are usually eaten fresh or dried but may be brewed in a tea or added to food.

I take magic mushrooms. Can it make it harder for me to become pregnant?

Studies have not been done to see if using magic mushrooms could make it harder for a woman to get pregnant.

Does taking magic mushrooms increase the chance for miscarriage?

Miscarriage can occur in any pregnancy. Users of magic mushrooms also report using other drugs such as cocaine, Ecstasy, LSD, and non-prescribed prescription drugs which may add more chance for miscarriage. Another concern is mistaking poisonous mushrooms for magic mushrooms which could lead to a medical emergency. Since users of magic mushrooms generally use other substances as well, it is unknown if using magic mushrooms increases the chance for miscarriage.

Does taking magic mushrooms increase the chance of birth defects?

In every pregnancy, a woman starts with a 3-5% chance of having a baby with a birth defect. This is called her background risk. Studies on women have not been done to see if using magic mushrooms increases the chance of birth defects. A single animal study showed no increased chance of physical birth defects.

Could taking magic mushrooms cause other pregnancy complications or long-term problems in behavior or learning for the baby?

There are no published studies on the long term effects of using magic mushrooms during pregnancy. It’s unknown if magic mushrooms can increase the chance for pregnancy complications or affect a baby’s brain or development.

Can I breastfeed while taking magic mushrooms?

Magic mushrooms have not been studied for use during breastfeeding. If you are taking magic mushrooms while breastfeeding and you suspect that the baby has unusual symptoms, contact the child’s healthcare provider. Be sure to talk to your health care provider about all of your breastfeeding questions.

If a man takes magic mushrooms, could it affect his fertility (ability to get partner pregnant) or increase the chance of birth defects?

There are no studies looking at male fertility or possible risks to a pregnancy when the father takes magic mushrooms. In general, exposures that fathers have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact- sheets/paternal-exposures-pregnancy/pdf/.

Selected References:

  • Hallock RM, et al. 2013.A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug Alcohol Depend. 130(1-3):245-8.
  • Rolsten C, 1997. Effects of chlorpromazine and psilocin on pregnancy of C57BL/10 mice and their offspring at birth. Anat Rec 157:311.
  • Timar L, Czeizal AE. 1997, Birth weight and congenital anomalies following poisonous mushroom intoxication during pregnancy. Reprod Toxicol 11: 861